Avac Event
Presenters:
Avac Event
A New-York based panel discussion featured doctors, PrEP users, activists, focusing on what PrEP means for women.
Guest Panelists:
Lynette Ford, MSW, GMHC
Jasmine, Woman currently using PrEP
Julie Lynn, Woman currently using PrEP
Poppy, Woman who was on PrEP when trying to get pregnant
Kimberleigh J. Smith, Harlem United Community AIDS Center
Shobha Swaminathan, MD, Division of Infectious Diseases, Department of Medicine Rutgers, The State University Of New
Jersey New Jersey Medical School
Guest Moderator:
Terri L. Wilder, MSW, Mt. Sinai Institute for Advanced Medicine & ACT UP/NY Women’s Caucus
The discussion is free and all are welcome. Light refreshments will be provided. For more information, email [email protected] or call (212) 367-1016. And spread the word! Flyer available for download below.
Avac Event
The fourth webinar in our series addressed a range of topics in HIV prevention research, hosted jointly by NAM and AVAC, and looked at the current situation regarding pre-exposure prophylaxis (PrEP) in Europe and the US. Presenters discussed the ongoing IPERGAY study in France and the PROUD study in England, and reviewed progress in the NEXT-PrEP and demonstration studies in the US.
It also discussed the implications of the negative results of the recent VOICE trial. The presentations were followed by a question and answer session with our expert speakers.
Avac Event
Results from the three-arm HIV prevention trial VOICE – Vaginal and Oral Interventions to Control the Epidemic – were recently presented at the 20th Conference on Retroviruses and Opportunistic Infections. The data showed that none of three interventions tested—daily oral tenofovir, daily oral TDF/FTC (Truvada), and daily 1% vaginal tenofovir gel—provided additional protection against HIV in this study, likely because few of the women in the trial used the products as directed.
This global advocates’ webinar included a presentation of the data from VOICE co-principal investigator Jeanne Marrazzo followed by a moderated discussion, which included clarifying questions around the trial itself as well as discussion of the implications these results have for ongoing and planned HIV prevention research and implementation.
Avac Event
PrEP researchers discussed ongoing trials of new oral PrEP interventions, including non-daily regimens (also described as “intermittent PrEP”) and new drugs such as maraviroc.
Principal investigators Bob Grant (ADAPT), Ken Mayer (NEXT-PrEP), Sheena McCormack (PROUD) and Jean-Michel Molina (ANRS Ipergay) joined the call. Their trials all seek to answer questions about strategies other than daily oral TDF/FTC and will provide important information on potential “second generation” oral PrEP.
Avac Event
The United States Conference on AIDS (USCA) is set for September 30 – October 3, 2012 at Caesars Palace Hotel in Las Vegas, NV. For nearly two decades, USCA has sought “to increase the strength and diversity of the community-based response to the HIV/AIDS epidemic through education, training, new partnerships, collaboration and networking. This year, USCA will work to highlight the changes in our movement that have brought us closer than ever to ending the epidemic, and ways that we can move forward as a community to make this dream a reality.
To accomplish this, NMAC and its program partners are adjusting the format of this year’s conference to ensure that attendees get the most out of their experience. Day-long institutes, historically held on the first day of the conference, will be replaced by the first ever Summit to End the HIV/AIDS Epidemic in America. And in order to make the agenda more flexible, seminars will be held each day of the conference and the length of workshop and roundtable sessions will be shortened so that attendees can maximize their learning experience.
USCA Presentation: PrEP can protect women and men against HIV! What do we need to know and do so we can translate results into public health impact?
Avac Event
Representatives from the US Food and Drug Administration, the US Centers for Disease Control and Prevention, the World Health Organization, the Southern African HIV Clinicians Society, the British HIV Association and the British Association for Sexual Health and Gilead Sciences will discuss various guidelines on the use of and FDA approval of daily TDF/FTC as PrEP.
This webinar will familiarize advocates with the types of regulatory and normative guidance documents that exist on PrEP—what they say, who they affect and what they may mean for policy and programming in various countries.
Avac Event
The Los Angeles County PrEP Workgroup and AVAC’s PxROAR program presented the webinar The Doc is In: Prescribing, Managing and Billing for PrEP (pre-exposure prophylaxis) for HIV Prevention. This webinar aimed to address some of the key issues around PrEP prescribing, such as concerns around drug resistance, cost and reimbursement, risk assessment and side effects, among others.
We were joined by Dr. Nika Seidman and Shannon Weber from the Bay Area Perinatal AIDS Center, and Dr. Tony Mills, a general medicine practitioner specializing in HIV care in Los Angeles.
View the full webinar here.
Avac Event
The final webinar of the Fall series discussed what is known from social and behavioral science and community experience about the definitions and perceptions of HIV risk among women that are relevant to their potential PrEP use.
Avac Event
The second in a series of webinars by the US Women and PrEP Working Group discussed the possibilities and challenges associated with serodiscordant couples using PrEP to help them achieve pregnancy safely.